Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0079731 (
B-cell lymphoma
)
16,671
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Perforin, a pore-forming protein toxin synthesized and stored in the cytoplasmic vesicles of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, is secreted when these effector lymphocytes encounter virus-infected or neoplastic cells. Perforin is encoded by a single-copy gene and is critical for immune homeostasis and defense of the organism against intracellular sepsis. A complete deficiency of perforin expression in either mice or humans is associated with a syndrome of immune insufficiency and severely deregulated lymphoid homeostasis. Humans who inherit inactivating mutations of perforin or defects in various parts of the cellular machinery that delivers perforin to the target cell suffer from
familial hemophagocytic lymphohistiocytosis
(
FHL
), a fatal condition necessitating bone marrow transplantation, usually in infancy. In mice, a high incidence of spontaneous
B cell lymphoma
has also been noted as the animals age. Across human populations, a number of polymorphisms that result in measurable, but suboptimal CTL activity have been noted, and some of these predispose to attenuated
FHL
or susceptibility to infectious disease, but in many cases, to no discernible disease predisposition. This chapter discusses the significance of human perforin polymorphisms, particularly those associated with diseases other than
FHL
, and recent advances in our understanding of perforin biology and function.
...
PMID:Infective, neoplastic, and homeostatic sequelae of the loss of perforin function in humans. 1771 10
Loss-of-function mutations in the gene coding for perforin (
PRF1
) markedly reduce the ability of cytotoxic T lymphocytes and natural killer cells to kill target cells, causing immunosuppression and impairing immune regulation. In humans, nearly half of the cases of type 2
familial hemophagocytic lymphohistiocytosis
are due to bi-allelic
PRF1
mutations. The partial inactivation of PRF1 due to mutations that promote protein misfolding or the common hypomorphic allele coding for the A91V substitution have been associated with lymphoid malignancies in childhood and adolescence. To investigate whether
PRF1
mutations also predispose adults to cancer, we genotyped 566 individuals diagnosed with melanoma (101), lymphoma (65), colorectal carcinoma (30) or ovarian cancer (370). The frequency of
PRF1
genotypes was similar in all disease groups and 424 matched controls, indicating that the
PRF1
status is not associated with an increased susceptibility to these malignancies. However, four out of 15 additional individuals diagnosed with melanoma and
B-cell lymphoma
during their lifetime expressed either PRF1
A91V
or the rare pathogenic PRF1
R28C
variant (p = 0.04), and developed melanoma relatively early in life. Both PRF1
A91V
- and PRF1
R28C
-expressing lymphocytes exhibited severely impaired but measurable cytotoxic function. Our results suggest that defects in human PRF1 predispose individuals to develop both melanoma and lymphoma. However, these findings require validation in larger patient cohorts.
...
PMID:Human perforin mutations and susceptibility to multiple primary cancers. 2373 37